N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-bromopropionamide | 937701-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-bromopropionamide
• 英文别名: 3-bromo-N-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]propanamide
• CAS: 937701-89-8
• 化学式: C₁₇H₁₃BrClFN₄O
• 分子量: 423.672
• InChiKey: RIPXNPZTBKTRRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-bromopropionamide 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 N-{4-[(3-chloro-4-fluorophenyl)amino]quinazolin-6-yl}-3-iodopropionamide
  参考文献：
  名称：

  Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer

  摘要：

  In our search for the development of novel SPECT radioligands for EGFR positive tumours, new potentially irreversible tyrosine kinase (TK) inhibitors are being explored. The radioiodination of N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-y}-3-bromopropionamide, a novel EGFR-TK inhibitor synthesised in our laboratory, was accomplished via halogen exchange. Purification by RP-HPLC gave [(125)1]-N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-iodopropionamide with a radiochemical purity higher than 95% and a high specific activity. In vitro studies indicate that both iodinated quinazoline and its bromo precursor inhibit A431 cell growth and also possess higher potency than the parent quinazoline to inhibit the EGFR autophosphorylation. In vivo stability studies suggest metabolization of the radioiodinated quinazoline indicating a short biological half-life. The in vitro results point out that these quinazoline derivatives could be promising candidates for SPECT imaging of EGFR positive tumours provided that they are selectively modified in order to achieve better in vivo radiochemical stability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.04.008
• 作为产物：
  描述：

  5-硝基靛红 在 tin(II) chloride dihdyrate 、 盐酸羟胺 、 溶剂黄146 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 N-{4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-bromopropionamide
  参考文献：
  名称：

  简便高效地合成4-苯胺基喹唑啉衍生物作为EGFR抑制剂并进行生物学评估。

  摘要：

  方便，有效地合成了一系列4-苯胺基喹唑啉衍生物，并通过MTT分析在三种人类癌细胞系H1975，HepG2和SMMC-7721中评估了它们的抗肿瘤活性。设计并合成了新的化合物19a-19h，以寻找功能强大的EGFR抑制剂，并探索喹唑啉环C-2位处的甲基是否对EGFR抑制具有积极作用。发现19a-19h的所有化合物对所有三种细胞系均有效，并且发现5种化合物（19c，19d和19f-19h）对H1975的毒性高于吉非替尼。SAR研究表明，喹唑啉环C-2位的甲基可以显着提高4-苯胺基喹唑啉的抗肿瘤能力。根据蛋白质印迹分析的结果也得出了相同的结论。在所有测试的化合物中，19g对H1975表现出极强的效力，IC50值为0.11μM，明显低于吉非替尼（1.23μM）。Western印迹分析的结果表明，化合物19c和19g可以显着抑制磷酸化EGFR的表达，尤其是19g几乎完全被抑制。

  DOI：

  10.1016/j.bmcl.2016.04.032

文献信息

• Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines
  作者：Ri-Dong Li、Xin Zhang、Qiao-Yan Li、Ze-Mei Ge、Run-Tao Li

  DOI：10.1016/j.bmcl.2011.04.096

  日期：2011.6

  basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. The effect of the synthesized compounds on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116. Two compounds (11d and 11f) were found more potent against all three cell lines and

  在联合策略的基础上，通过二硫代氨基甲酸酯与4-苯胺基喹唑啉的结合，设计合成了一系列新的EGFR抑制剂。通过MTT测定法在三种人癌细胞系：MDA-MB-468，SK-BR-3和HCT-116中评估了合成化合物对细胞增殖的作用。发现两种化合物（11d和11f）对所有三种细胞系均更有效力，而五种化合物（11a，11d – 11g））被发现对MDA-MB-468和SK-BR-3都比拉帕替尼更有效。SAR研究表明，喹唑啉C6和C7位置的取代基，二硫代氨基甲酸酯部分的胺成分和连接基极大地影响了活性。这项工作为有效的酪氨酸激酶抑制剂的制备提供了有希望的新策略。
• Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging
  作者：Célia Fernandes、Isabel C. Santos、I. Santos、Hans-Jurgen Pietzsch、Jens-Uwe Kunstler、Werner Kraus、Ana Rey、Nikos Margaritis、Athanasia Bourkoula、Aris Chiotellis、Maria Paravatou-Petsotas、Ioannis Pirmettis

  DOI：10.1039/b802021c

  日期：——

  the tricarbonyl approach, the fac-[Tc(CO)3]+ unit is anchored by two different monoanionic chelators bearing the quinazoline derivatives (3-chloro-4-fluorophenyl)quinazoline-4,6-diamine (2) and (3-bromophenyl)quinazoline-4,6-diamine (3). Both chelators have a N2O donor atom set, but one contains a pyrazolyl ring (L55H) and the other contains a pyridine unit (L66H). In both cases the conjugation of

  这 喹唑啉 衍生品 （3-氯-4-氟苯基）喹唑啉-4,6-二胺（2）和（3-溴苯基）喹唑啉-4,6-二胺（3）使用“ 4 +1”混合配体系统[Tc（NS 3）（CN-R）]和三羰基部分fac- [Tc（CO）3 ] +标记为99m Tc 。在“ 4 +1”方法中，tech（III）由单齿稳定异氰化物带有喹唑啉片段（L 1 1，L 2 2）和四齿三脚架配体 三（2-巯基乙基）胺（NS 3）。在“ 4 +1”方法中，分两步进行99m Tc标记，即络合物[Tc（NS 3）（L 1 1）]（7a）和[Tc（NS 3）（L 2 2））]（8a）的收率约为50-70％。在三羰基方法中，fac- [Tc（CO）3 ] +单元被两个不同的单阴离子固定螯合剂 轴承 喹唑啉 衍生品 （3-氯-4-氟苯基）喹唑啉-4,6-二胺（2）和（3-溴苯基）喹唑啉-4,6-二胺（3）。两个都螯合剂具有一个N 2 O供体原子组，但一个包含一个吡唑基环（L
• Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors
  作者：Zheng Wang、Xue Wu、Li Wang、Jiao Zhang、Jianli Liu、Zhongxing Song、Zhishu Tang

  DOI：10.1016/j.bmcl.2016.04.032

  日期：2016.6

  Series of 4-anilinoquinazoline derivatives were conveniently and efficiently synthesized and their antitumor activities were evaluated by MTT assay in three human cancer cell lines: H1975, HepG2 and SMMC-7721. New compounds 19a-19h were designed and synthesized to seek for powerful EGFR inhibitors and to explore whether methyl group at C-2 position of quinazoline ring has a positive effect on EGFR

  方便，有效地合成了一系列4-苯胺基喹唑啉衍生物，并通过MTT分析在三种人类癌细胞系H1975，HepG2和SMMC-7721中评估了它们的抗肿瘤活性。设计并合成了新的化合物19a-19h，以寻找功能强大的EGFR抑制剂，并探索喹唑啉环C-2位处的甲基是否对EGFR抑制具有积极作用。发现19a-19h的所有化合物对所有三种细胞系均有效，并且发现5种化合物（19c，19d和19f-19h）对H1975的毒性高于吉非替尼。SAR研究表明，喹唑啉环C-2位的甲基可以显着提高4-苯胺基喹唑啉的抗肿瘤能力。根据蛋白质印迹分析的结果也得出了相同的结论。在所有测试的化合物中，19g对H1975表现出极强的效力，IC50值为0.11μM，明显低于吉非替尼（1.23μM）。Western印迹分析的结果表明，化合物19c和19g可以显着抑制磷酸化EGFR的表达，尤其是19g几乎完全被抑制。
• Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer
  作者：Célia Fernandes、Cristina Oliveira、Lurdes Gano、Athanasia Bourkoula、Ioannis Pirmettis、Isabel Santos

  DOI：10.1016/j.bmc.2007.04.008

  日期：2007.6

  In our search for the development of novel SPECT radioligands for EGFR positive tumours, new potentially irreversible tyrosine kinase (TK) inhibitors are being explored. The radioiodination of N-4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-y}-3-bromopropionamide, a novel EGFR-TK inhibitor synthesised in our laboratory, was accomplished via halogen exchange. Purification by RP-HPLC gave [(125)1]-N-4-[(3-chloro-4-fluorophenyl)amino]quinazoline-6-yl}-3-iodopropionamide with a radiochemical purity higher than 95% and a high specific activity. In vitro studies indicate that both iodinated quinazoline and its bromo precursor inhibit A431 cell growth and also possess higher potency than the parent quinazoline to inhibit the EGFR autophosphorylation. In vivo stability studies suggest metabolization of the radioiodinated quinazoline indicating a short biological half-life. The in vitro results point out that these quinazoline derivatives could be promising candidates for SPECT imaging of EGFR positive tumours provided that they are selectively modified in order to achieve better in vivo radiochemical stability. (C) 2007 Elsevier Ltd. All rights reserved.